Trials / Completed
CompletedNCT01710514
A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment
A Multi-Center, Randomized, Open-Label, Parallel Group Study of FE 999913 Vaginal Tablet 100 mg in Japanese Female Patients Undergoing Fertility Treatment [In Vitro Fertilization/Embryo Transfer (IVF-ET)]
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 20 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of the study are to verify sufficient supplementation of luteal hormone after administrating FE999913 Vaginal Tablet twice a day (BID) or three times a day (TID) and to determine the efficacy and safety of FE999913 Vaginal Tablet in Japanese women undergoing fertility treatment with IVF-ET (a fresh embryo transfer).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FE 999913 vaginal tablet |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2012-10-19
- Last updated
- 2014-09-05
- Results posted
- 2014-08-19
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01710514. Inclusion in this directory is not an endorsement.